Revolutionizing Cancer Treatment: How Defence Therapeutics' Platform Enhances Drug Efficacy and Targets Cancer Cells with Precision

Defence's platform is unique, it enhances the efficacy of practically any existing drugs by develivering it more precisely to the cancer cells, causing less side effects to the patients. On top of that, the Accum™ variant, AccuTOX, is acting as an anti-cancer agent, meaning it has 2 modes of action.

Defence plans to have begun two clinical trials on its 100% owned products: AccuTOX as an anti-cancer molecule targeting melanoma in combination with anti-PD1 and the ARM-X, as a cell-based vaccine targeting pancreatic cancer. At least one phase I is expected to be completed within this timeline. In addition, Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred.

The versatility of the Accum platform is key to attract strategic partnerships. An example is our ADC program: we are currently in the process of demonstrating that Accum can increase the efficacy and reduce the dosing of any existing ADCs. Which means that we can potentially "fix" any ADC companies who have efficacy and dosing issues by adding Accum, making Defence well positioned to attract strategic partners.

Defence's ARM-X vaccine is exactly what it's all about. The ARM-X vaccine represents a leading vaccination platform due to its ease in manufacturing and the therapeutic potency that this allogeneic off-the-shelf vaccine can provide. Defence scientific team only needs a small tumour biopsy from the patient to complete its ARM-X vaccine meaning that within less than 24 hours the vaccine is ready to give to the patient. Defence has shown preclinically that the vaccine works well on solid tumours as 4 cancer models were already tested with great results: T-cell lymphoma, melanoma, pancreatic and ovarian cancers.

Financial stability is indeed critical. Defence is currently in discussions with Canadians, Americans and European strategic potential investors/funds to secure its R&D and clinical trials programs. Clinical trials will be the priority while funds will be allocated to preclinical programs with partnerships potential like radiopharmaceuticals and ADCs projects. Discussions with potential partnership are ongoing. The company is also evaluating potential US listings on the NYSE or Nasdaq in 2025.